Avanos Medical, Inc.
NYSE:AVNSMedical - Devices
+$0.06 today
- Market cap
- $1.17B
- Beta
- 1.57
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$1.50
Volume 0.43M
Average 1.49M
AVNS Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Avanos Medical, Inc.NYSE: AVNS
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$300K, compared with $25.1M a year earlier. Trailing-twelve-month accounts receivables was $5.5M.
Context
- Accounts receivables amounted to 4.4% of revenue in FY2025, up 3.4 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$300K or moves back toward the trailing-twelve-month quarterly average of $1.38M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 30.9M USD
- Year-over-year change
- +568.2%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.9M | +568.2% |
| FY2024 | 2024-12-31 | (6.6M) | -116.9% |
| FY2023 | 2023-12-31 | 39M | +257.9% |
| FY2022 | 2022-12-31 | (24.7M) | -128.7% |
| FY2021 | 2021-12-31 | (10.8M) | — |
Accounts Receivables vs competitors
How AVNS compares with its peers on the latest reported figures
- AVNS's LTM Mar 2026 accounts receivables of $5.5M is the 2nd largest of the 11 companies compared; the peer median is $549.5K.
- Its year-over-year change of -46.6% is the 6th highest of 10, against a peer median of +27.2%.
- Accounts receivables amounts to 0.8% of revenue for AVNS, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $6M | +103.9% | +65.1% | 0.0% | |
| LTM Mar 2026 | $5.5M | -46.6% | — | 0.8% | |
CBLLCeriBell, Inc. | LTM Mar 2026 | $4.33M | +27.2% | +1.8% | 4.6% |
| LTM Apr 2026 | $3.7M | -169.8% | — | 0.4% | |
| LTM Mar 2026 | $3.56M | +210.9% | — | 1.7% | |
| LTM Mar 2026 | $3.41M | -86.4% | — | 5.4% | |
| LTM Mar 2026 | $3.13M | +159.8% | +8.3% | 7.7% | |
| LTM Mar 2026 | $2.6M | -979.1% | -62.7% | 0.5% | |
| LTM Mar 2026 | $2.3M | +273.6% | — | 1.4% | |
| LTM Mar 2026 | $1.1M | -82.4% | — | 1.3% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding AVNS) | $549.5K | +27.2% | +5.0% | 1.4% | |
Competitors are the stored peer set for AVNS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.2M | 50.5M | (61.8M) | (392.1M) | (72.9M) |
| Depreciation & Amortization | 38.3M | 47.7M | 46.1M | 45.5M | 38.9M |
| Deferred Income Tax | (3.4M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.2M | 15.9M | 15.8M | 13.8M | 12.6M |
| Change in Working Capital | 26M | (24.3M) | (18M) | 35M | 9.8M |
| Accounts Receivables | (10.8M) | (24.7M) | 39M | (6.6M) | 30.9M |
| Inventory | 17.2M | (30.9M) | 4.7M | 39M | 200K |
| Accounts Payables | (11.9M) | 35.4M | (14.4M) | (900K) | 600K |
| Other Working Capital | 31.5M | (4.1M) | (47.3M) | 3.5M | (21.9M) |
| Other Non-Cash Items | 8M | 1.1M | 50.3M | 398.5M | 86.3M |
| Operating Cash Flow | 87.3M | 90.9M | 32.4M | 100.7M | 74.7M |
| Capital Expenditures | (21M) | (19.3M) | (17.8M) | (17.8M) | (31.6M) |
| Acquisitions (Net) | 0 | (116.1M) | 39.4M | (9.7M) | (28M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (1M) |
| Investing Cash Flow | (21M) | (135.4M) | 21.6M | (27.5M) | (60.6M) |
| Debt Repayment | (50M) | 103.4M | (64.7M) | (33.6M) | (34.4M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 700K |
| Common Stock Repurchased | (11.5M) | (45.5M) | (19.1M) | (12.8M) | (3.3M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6.2M | (1.2M) | (10.4M) | (2.7M) | 0 |
| Financing Cash Flow | (55.3M) | 56.7M | (94.2M) | (49.1M) | (37M) |
| Effect of Forex Changes | (4M) | (3M) | 200K | (4.1M) | 5M |
| Net Change in Cash | 7M | 9.2M | (40M) | 20M | (17.9M) |
| Free Cash Flow | 66.3M | 71.6M | 14.6M | 82.9M | 43.1M |
Avanos Medical, Inc.
NYSE:AVNS
Intrinsic Alpha fair value
Locked
Current Price
$24.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.